Clinical Report: Dual Axis Stratification of Immunological Coagulation Reveals Ultra High-Risk Phenotypes in Systemic Sclerosis
Overview
This study identifies a dual-axis stratification approach for systemic sclerosis (SSc) that reveals high-risk patient phenotypes based on immune and coagulation markers.
Background
Systemic sclerosis is a complex autoimmune disease with diverse clinical manifestations and variable prognosis. The interplay between immune activation, inflammation, and coagulation is critical in understanding disease progression and patient outcomes.
Data Highlights
Index
Mortality Risk
Hazard Ratio (HR)
95% Confidence Interval (CI)
P-value
Concurrent elevation of SII and DPR
7.41-fold
7.41
2.09–26.30
0.002
Key Findings
Patients with both elevated SII and DPR had a 7.41-fold higher mortality risk compared to those with low levels.
The multi-index prognostic score achieved an area under the curve of 0.747 for mortality prediction.
K-means clustering identified three distinct IICF molecular endotypes.
Elevation of either SII or DPR alone did not reach statistical significance for mortality risk.
Clinical Implications
The dual-axis stratification approach may enhance risk assessment in SSc patients, allowing for more tailored therapeutic strategies. Understanding the interplay between immune and coagulation pathways can inform clinical decision-making and improve patient management.
Conclusion
The findings highlight the significance of a comprehensive IICF network in predicting outcomes in systemic sclerosis, suggesting that integrated approaches may better inform clinical practice.
Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.
